Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00033799
DRKS00033799
Not Yet Recruiting
N/A

A prospective clinical multicenter study to evaluate the safety, performance and subject satisfaction when using hyaluronic acid fillers from the Mona Lisa product range by GENOSS to build facial volume and contour the face and their comparison to products from the manufacturers Across, Allergan, Galderma and Vivacy

GENOSS0 sites700 target enrollmentMarch 5, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionshypovolaemia, hypotrophy, atrophy, loss of contour, excess skin

Overview

Phase
N/A
Intervention
Not specified
Conditions
hypovolaemia, hypotrophy, atrophy, loss of contour, excess skin
Sponsor
GENOSS
Enrollment
700
Status
Not Yet Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 5, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
Female

Investigators

Sponsor
GENOSS

Eligibility Criteria

Inclusion Criteria

  • •Aesthetic desire to increase volume or emphasize the contours of the face
  • •\- Female participants aged 18 years or older
  • •\- Subjects who would also have been treated outside the study with a hyaluronic acid gel intended for the region.
  • •\- Injection on both sides and on the same sides
  • •\- Legal capacity as well as the existence of written consent to participate in the study, the data protection declaration as well as the signed information form and consent to photo documentation after detailed information and advice

Exclusion Criteria

  • •\- Additional injections of the same region within the testing period
  • •\- History of hypersensitivity or allergy to hyaluronic acid, its ingredients or to products with a similar chemical structure
  • •\- Known hypersensitivity or allergy to lidocaine or products of the same substance class
  • •\- Known hypersensitivity to gram\-positive bacteria
  • •\- Tendency to hypertrophic scars or keloid formation
  • •\- Subject with active inflammatory process or infectious event
  • •\- Subject suffering from a serious acute or chronic disease
  • •\- Taking blood thinning medications
  • •\- Scars in the area to be treated
  • •\- Excessive excess skin in the area to be treated

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
se of biosynthetic material (MegaDerm) as reinforcing buttress material of anastomotic sites after gastric resectioNeoplasms
KCT0002715Korea University Anam Hospital100
Completed
Phase 4
Clinical study for HemoRel-A® in Hemophilia A patientsHealth Condition 1: null- Hemophilia A
CTRI/2018/05/013790Dr Savita Rangarajan44
Completed
N/A
A prospective multicenter study for the evaluation of a Point-of-Care Test (POCT) for the diagnosis of celiac diseaseK90.0Coeliac disease
DRKS00012499Charité Campus Benjamin Franklin1,100
Not Yet Recruiting
N/A
Prospective, clinical, multicentric study to evaluate the influence of the length of the membranous urethra on stress urinary incontinence after robot-assisted radical prostatectomyC61Malignant neoplasm of prostate
DRKS00024607Krankenhaus der Barmherzigen Brüder Wien500
Not Yet Recruiting
N/A
A multicenter prospective clinical study for the treatment of spleen and kidney insufficiency metrorrhagia and metrostaxis with Lingnan Hemostatic Prescription Erren Decoctio
ITMCTR1900002640The First Affiliated Hospital of Guangzhou University of Chinese Medicine